Antifungal susceptibility of epigallocatechin 3-O-gallate (EGCg) on clinical isolates of pathogenic yeasts
Antifungal susceptibility of epigallocatechin 3-O-gallate (EGCg) on clinical isolates of pathogenic yeasts
复制标题
DOI：
10.1016/j.bbrc.2006.06.037
复制
发表时间：
2006-08-25
影响因子：
3.1
通讯作者：
Takatori, Kosuke
中科院分区：
文献类型：
--
作者：
Park, Bong Joo;Park, Jong-Chul;Takatori, Kosuke
本文首次报道了7种念珠菌的21株临床分离株对表没食子儿茶素没食子酸酯（EGCg）的敏感性，并与6种抗真菌药物进行了比较，这些药物分别为：阿替霉素B（AMPH）、氟康唑（FLCZ）、氟胞嘧啶（5 FC）、伊曲康唑（ITCZ）、米卡芬净（MCFG）和咪康唑（MCZ）。使用遵循国家临床实验室标准委员会（NCCLS）M27-A指南的方法。在供试菌种中，光滑念珠菌对EGCg的敏感性最高（MIC 50，0.5-1 μ g/ml和MIC 90，1-2 μ g/ml），优于FLCZ，尽管它们对AMPH、5 FC、MCFG的敏感性略低。ITCZ。还有MCZ。季氏念珠菌和近平滑念珠菌（MIC 50，1-4 μ g/ml和MIC 90，2-16 μ g/ml）也对EGCg敏感，尽管它们对EGCg的敏感性似乎略低于C。glabrata和其他测试的抗真菌剂。而且。克柔念珠菌菌株对EGCg的敏感性（MIC 50，2 μ g/ml和MIC 90，4-8 μ g/ml）比对5 FC和FLCZ的敏感性高约2- 8倍。我们的数据表明，EGCg可以抑制临床致病性念珠菌属，虽然抗真菌药敏的EGCg浓度略高于测试的抗真菌药物的整体。基于这些结果，我们建议EGCg可以有效地用作抗真菌治疗的可能药剂或辅助剂。(c)2006年爱思唯尔公司All rights reserved.
This is the first report to investigate the antifungal susceptibility of 21 clinical isolates of seven Candida species to epigallocatechin 3-O-gallate (EGCg) and to compare with six antifungal agents, amphotericin B (AMPH), fluconazole (FLCZ), flucytosin (5FC), itraconazole (ITCZ), micafungin (MCFG), and miconazole (MCZ), using a method following the National Committee for Clinical Laboratory Standards (NCCLS) M27-A guidelines. Among the tested species, Candida glabrata exhibited the highest susceptibility to EGCg (MIC50, 0.5-1 mu g/ml and MIC90, 1-2 mu g/ml) compared favorably with FLCZ, although they were slightly less susceptible than to AMPH, 5FC, MCFG. ITCZ. and MCZ. Candida guilliemondii and Candida parapsilosis (MIC50, 1-4 mu g/ml and MIC90, 2-16 mu g/ml) were also susceptible to EGCg, although they appear to be slightly less susceptible to EGCg than C. glabrata and the other antifungal agents tested. Moreover. the susceptibility of Candida krusei strains (MIC50, 2 mu g/ml and MIC90, 4-8 mu g/ml) to EGCg was approximately 2- to 8-fold higher than those of 5FC and FLCZ. Our data indicate that EGCg can inhibit clinically pathogenic Candida species, although the concentrations of EGCg for antifungal susceptibility were slightly higher than those of tested antifungal agents on the whole. Based on these results, we suggest that EGCg may be effectively used as a possible agent or adjuvant for antifungal therapy in Candidiasis. (c) 2006 Elsevier Inc. All rights reserved.